trending Market Intelligence /marketintelligence/en/news-insights/trending/3l0p82-q5byl7yayk7j3za2 content esgSubNav
In This List

Mesoblast names CFO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mesoblast names CFO

Mesoblast Ltd. appointed Josh Muntner to the position of CFO.

Muntner, who will be based in New York, replaces outgoing CFO Paul Hodgkinson.

Previously, Muntner led corporate development and financial transactions at biotechnology company ContraFect Corp.

Ignite Partners advised the company on Muntner's appointment.

Australia-based Mesoblast develops cell-based medicines.